ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met ...

AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated ...

AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...

Three-week nodal radiotherapy “is the international standard of care” for early breast cancer, according to Charlotte E. Coles, PhD. A 10-year update of the CheckMate 067 trial suggests that ...

Nicolas Girard, MD, head of the Curie-Montsouris Thorax Institute, discusses patient-reported outcomes (PROs) from the phase 2 LUMINOSITY trial of telisotuzumab vedotin (Teliso-V) in non–small cell ...

Aussie shares plummet after US rate hike; Qantas shamed in consumer group award; Major flood warning for NSW city. © 2024 Nine Entertainment Co.

NEW YORK – AbbVie's MET-targeting antibody-drug conjugate telisotuzumab vedotin led to durable responses in patients with c-MET-overexpressing EGFR-wild-type non-small cell lung cancer in a Phase II ...

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing ...

Presentations include data on mirvetuximab soravtansine (ELAHERE®) and c-Met targeting ADCs, telisotuzumab vedotin (Teliso-V) and telisotuzumab adizutecan (ABBV-400). AbbVie’s ADCs are designed to ...